Link: https://www.alzforum.org/therapeutics/bpn14770
Description: BPN14770 is a small molecule that boosts brain cAMP and improves memory in animal models of AD and Fragile X. It is being developed by Shionogi Pharma and Tetra Therapeutics, and has completed Phase 1 and 2 trials in healthy volunteers and patients with AD and Fragile X.
DA: 72 PA: 80 MOZ Rank: 63
Link: https://fragilex.org/opportunities-for-families/tetra-bpn14770/
Description: Who Can Participate?What Will Happen in The Study?What Are The Good Things That Can Happen from This Research?What Are The Bad Things That Can Happen from This Research?Who Can I Contact For More Information About This Study?If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks. The following is a list of some of the study proceduresthat will happen during the study: 1. Participant cognitive and behavior testing 2. Blood draws 3. Parent/caregiver questionnaires For more information, ch...See more on fragilex.orgExplore further If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks. The following is a list of some of the study proceduresthat will happen during the study: 1. Participant cognitive and behavior testing 2. Blood draws 3. Parent/caregiver questionnaires For more information, ch...
If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks. The following is a list of some of the study proceduresthat will happen during the study: 1. Participant cognitive and behavior testing 2. Blood draws 3. Parent/caregiver questionnaires For more information, ch...DA: 50 PA: 17 MOZ Rank: 40
Link: https://www.shionogi.com/global/en/news/2020/11/e-201102-2.html
Description: WEBNov 2, 2020 · BPN14770 is a drug candidate that enhances memory formation and improves cognitive function in patients with Fragile X Syndrome (FXS), a genetic form of …
DA: 64 PA: 80 MOZ Rank: 16
Link: https://www.alzheimers.gov/clinical-trials/bpn14770-early-alzheimers-picasso
Description: WEBA Phase 2 trial of BPN14770, a small molecule that affects a protein involved in cognition and memory, in people with early-stage Alzheimer's disease. Learn about the study …
DA: 81 PA: 82 MOZ Rank: 42
Link: https://tetratherapeutics.com/tetra-therapeutics-announces-positive-topline-results-from-phase-2-study-of-bpn14770-in-patients-with-fragile-x-syndrome/
Description: WEBBPN14770 is a novel therapeutic agent that selectively inhibits phosphodiesterase‐4D (PDE4D). In preclinical studies, BPN14770 promoted the maturation of connections between neurons, which is …
DA: 43 PA: 19 MOZ Rank: 60
Link: https://www.businesswire.com/news/home/20220712005003/en/Tetra-Therapeutics-Initiates-Phase-2b3-Clinical-Studies-of-Investigational-Drug-BPN14770-in-Fragile-X-Syndrome
Description: WEBJul 12, 2022 · BPN14770 is an investigational new drug that selectively inhibits phosphodiesterase-4D to enhance early and late stages of memory formation.
DA: 15 PA: 78 MOZ Rank: 80
Link: https://www.shionogi.com/global/en/news/2020/11/e-201102-2.html
Description:
DA: 65 PA: 31 MOZ Rank: 17
Link: https://www.nature.com/articles/s41386-018-0178-6
Description: WEBAug 14, 2018 · In mice engineered to express PDE4D with this primate-specific sequence, BPN14770 was 100-fold more potent for improving memory than in wild-type mice; …
DA: 63 PA: 58 MOZ Rank: 56
Link: https://www.businesswire.com/news/home/20201102005309/en/Tetra-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-Study-of-BPN14770-in-Patients-with-Fragile-X-Syndrome
Description: WEBNov 2, 2020 · BPN14770 is a novel therapeutic agent that selectively inhibits phosphodiesterase‐4D (PDE4D). In preclinical studies, BPN14770 promoted the …
DA: 96 PA: 13 MOZ Rank: 82
